Mon, April 15, 2013
Fri, April 12, 2013
Thu, April 11, 2013
[ Thu, Apr 11th 2013 ] - Market Wire
15 PM EDT
Wed, April 10, 2013
Tue, April 9, 2013
[ Tue, Apr 09th 2013 ] - Market Wire
30 a.m. ET
Mon, April 8, 2013
Sat, April 6, 2013
Fri, April 5, 2013
Thu, April 4, 2013
Wed, April 3, 2013
Tue, April 2, 2013
Mon, April 1, 2013
Fri, March 29, 2013
Thu, March 28, 2013
Wed, March 27, 2013
Tue, March 26, 2013
Mon, March 25, 2013
[ Mon, Mar 25th 2013 ] - Market Wire
Health Canada Decision Appealed
Sun, March 24, 2013
Fri, March 22, 2013
Thu, March 21, 2013
Wed, March 20, 2013
[ Wed, Mar 20th 2013 ] - Market Wire
00am ET
Tue, March 19, 2013
Mon, March 18, 2013

Peregrine Announces Three Abstracts Accepted for Presentation at AACR 2013 Annual Meeting


//health-fitness.news-articles.net/content/2013/ .. or-presentation-at-aacr-2013-annual-meeting.html
Published in Health and Fitness on by Market Wire   Print publication without navigation


April 01, 2013 16:00 ET

Peregrine Announces Three Abstracts Accepted for Presentation at AACR 2013 Annual Meeting

TUSTIN, CA--(Marketwire - Apr 1, 2013) - Peregrine Pharmaceuticals, Inc. (NASDAQ: [ PPHM ]), a biopharmaceutical company developing first-in-class monoclonal antibodies focused on the treatment and diagnosis of cancer, today announced the acceptance of three preclinical abstracts scheduled for poster presentations at the 104th Annual Meeting of the American Association for Cancer Research (AACR), to be held April 6-10, 2013 in Washington, DC. Data to be presented include studies investigating the immune stimulating mechanism of action of Peregrine's lead phosphatidylserine (PS)-targeting oncology clinical candidate bavituximab and the anti-tumor and imaging potential of other PS-targeting constructs.

Abstract Details:

[ Abstract Number 1244 ]
Presentation Title: Phosphatidylserine-targeting antibody reactivates tumor immunity and destroys tumor vasculature in mice
Presentation Time: Monday, Apr 08, 2013, 1:00 PM - 5:00 PM EDT
Location: Hall A-C, Poster Section 5
Poster Board Number: 24
Author Block: Yi Yin, Xianming Huang, Dan Ye, Philip Thorpe. UT Southwestern Medical Ctr., Dallas, TX

[ Abstract Number 2850 ]
Presentation Title: Predicting anti-tumor responses to phosphatidylserine targeting antibodies using tumor imaging
Presentation Time: Tuesday, Apr 09, 2013, 8:00 AM - 12:00 PM EDT
Location: Hall A-C, Poster Section 21
Poster Board Number: 22
Author Block: Jian Gong1, Richard Archer1, Van Nguyen1, Christopher C.W. Hughes2, Jeff Hutchins1, Bruce Freimark1. 1. Peregrine Pharmaceuticals, Inc., Tustin, CA; 2. University of California, Irvine, Irvine, CA

[ Abstract Number: 4326 ]
Presentation Title: Phosphatidylserine-targeting 'betabodies' for the treatment of cancer
Presentation Time: Tuesday, Apr 09, 2013, 1:00 PM - 5:00 PM EDT
Location: Hall A-C, Poster Section 36
Poster Board Number: 9
Author Block: Xianming Huang1, Dan Ye1, Troy Luster2, E. Sally Ward1, Philip Thorpe1. 1. UT Southwestern Medical Ctr., Dallas, TX; 2. Human Genome Science, Maryland, MD

About Peregrine Pharmaceuticals, Inc.

Peregrine Pharmaceuticals, Inc. is a biopharmaceutical company with a portfolio of innovative monoclonal antibodies in clinical trials focused on the treatment and diagnosis of cancer. The company is pursuing multiple clinical programs in cancer with its lead product candidate bavituximab and novel brain cancer agent Cotara®. Peregrine also has in-house cGMP manufacturing capabilities through its wholly-owned subsidiary Avid Bioservices, Inc. ([ www.avidbio.com ]), which provides development and biomanufacturing services for both Peregrine and third-party customers. Additional information about Peregrine can be found at [ www.peregrineinc.com ].



Publication Contributing Sources